Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

My opinion on what happened is that there

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
gestalt2 Member Profile
 
Followed By 6
Posts 932
Boards Moderated 1
Alias Born 04/13/16
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2018 5:06:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2018 4:32:34 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 9/10/2018 3:50:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:26:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:25:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:24:14 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 9/7/2018 5:31:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2018 4:33:16 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/31/2018 4:35:00 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 8/31/2018 4:33:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2018 4:34:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2018 7:33:49 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2018 5:33:42 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/14/2018 5:32:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2018 4:39:40 PM
Annual Report (10-k) Edgar (US Regulatory) - 7/27/2018 5:03:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/12/2018 4:32:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/27/2018 9:02:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/22/2018 5:02:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2018 7:49:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2018 7:44:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
gestalt2   Friday, 11/10/17 06:45:00 PM
Re: BlackDoggie post# 18100
Post # of 29063 
My opinion on what happened is that there seemed to be some confusion between cytodyn and the FDA, the FDA wanted a face to face to resolve something. I feel that cytodyn is asking or expecting a wider label and thought they would get it. the FDA lowered the enrollment to 30 because tai med was allowed to have that trial size but they were looking at a much narrower label. The fact that cytodyn did not really elaborate on why this happened or what the specifics of the discussion suggests there was some sort of misunderstanding that Nader should have been on top of. It could be the 50patients and 300 safety data solves this and ensures a broad label. It could very well be that the FDA could have stuck with the original 150 trial size if at that time cytodyn was asking for a broad label. Either way, I think it is safe to assume Nader was a little loose with the details of the combo trial.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist